This new iteration of the drug is undergoing clinical trials, but Gilead contends that it will be more effective at treating HCV. Clinical trials are expected to finish later this year.
In fall 2014, eight generic drug makers received approval to produce Sovaldi for 91 countries, excluding China, according to the report. The geographic restrictions have sparked criticism from such groups as Doctors Without Borders. China has approximately 30 million people with HCV.
More articles on gastroenterology:
FDA approves generic version of GERD treatment drug
14 statistics on gastroenterologist burnout
AGA addresses duodenoscope infection risks
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.